1. Home
  2. CASI vs RMCO Comparison

CASI vs RMCO Comparison

Compare CASI & RMCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASI
  • RMCO
  • Stock Information
  • Founded
  • CASI 1991
  • RMCO 2021
  • Country
  • CASI China
  • RMCO United States
  • Employees
  • CASI N/A
  • RMCO N/A
  • Industry
  • CASI Biotechnology: Pharmaceutical Preparations
  • RMCO Multi-Sector Companies
  • Sector
  • CASI Health Care
  • RMCO Miscellaneous
  • Exchange
  • CASI Nasdaq
  • RMCO Nasdaq
  • Market Cap
  • CASI 35.8M
  • RMCO 35.9M
  • IPO Year
  • CASI 1996
  • RMCO N/A
  • Fundamental
  • Price
  • CASI $1.84
  • RMCO $2.90
  • Analyst Decision
  • CASI Strong Buy
  • RMCO
  • Analyst Count
  • CASI 1
  • RMCO 0
  • Target Price
  • CASI $4.00
  • RMCO N/A
  • AVG Volume (30 Days)
  • CASI 305.0K
  • RMCO 55.1K
  • Earning Date
  • CASI 11-13-2025
  • RMCO 11-14-2025
  • Dividend Yield
  • CASI N/A
  • RMCO 0.35%
  • EPS Growth
  • CASI N/A
  • RMCO N/A
  • EPS
  • CASI N/A
  • RMCO N/A
  • Revenue
  • CASI $31,564,000.00
  • RMCO $2,641,171.00
  • Revenue This Year
  • CASI N/A
  • RMCO N/A
  • Revenue Next Year
  • CASI N/A
  • RMCO N/A
  • P/E Ratio
  • CASI N/A
  • RMCO N/A
  • Revenue Growth
  • CASI 36.64
  • RMCO 292.46
  • 52 Week Low
  • CASI $1.09
  • RMCO $0.87
  • 52 Week High
  • CASI $7.50
  • RMCO $3.01
  • Technical
  • Relative Strength Index (RSI)
  • CASI 51.04
  • RMCO 78.38
  • Support Level
  • CASI $1.77
  • RMCO $2.10
  • Resistance Level
  • CASI $2.08
  • RMCO $2.22
  • Average True Range (ATR)
  • CASI 0.20
  • RMCO 0.18
  • MACD
  • CASI 0.02
  • RMCO 0.06
  • Stochastic Oscillator
  • CASI 71.84
  • RMCO 94.50

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

Share on Social Networks: